The global antibody drug conjugates market size reached US$ 6.3 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 22.4 Billion by 2028, exhibiting a growth rate (CAGR) of 23.54% during 2022-2028. Antibody drug conjugates (ADCs) are highly potent biological drugs comprising tumor-targeting antibodies, which are chemically attached to a cytotoxic effector molecule. They deliver cytotoxic anticancer agents to affected cells by connecting them to monoclonal antibodies (mAb) through biodegradable linkers and allowing sensitive bifurcation between healthy and diseased tissues. They assist in increasing the cell-killing potential of mAb, enhancing drug tolerability, and limiting systematic exposure compared to standard chemotherapy bioactive compounds. At present, they are administered intravenously into the bloodstream to avoid gastric acid and proteolytic enzyme degradation of the mAb. Antibody Drug Conjugates Market Trends: Due to sedentary lifestyles and the rising number of individuals who smoke and drink regularly, there is an increase in the prevalence of cancer around the world. This, in confluence with the escalating demand for cost-effective and successful cancer treatments, represents one of the key factors bolstering the growth of the market. Apart from this, the existing linkers often release payloads nonspecifically and lead to off-target toxicity, which severely affects the development of ADCs. As a result, leading players are continuously funding their research and development (R&D) projects to optimize the existing chemical triggers and develop novel chemical triggers to generate highly selective linkers. They are also coming up with novel linker-antibody attachments to produce stable and homogenous ADCs and additional linker-payload attachments to allow the expansion of payloads. Moreover, they are focusing on improving the absorption, distribution, metabolism, and excretion, which is creating a favorable market outlook. Other major factors, including considerably improving healthcare infrastructure, increasing awareness about therapies available for cancer treatments, and the introduction of cleavable linker technology, are anticipated to propel the market growth. Key Market Segmentation: IMARC Group provides an analysis of the key trends in each sub-segment of the global antibody drug conjugates market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on component, target, application and end user. Breakup by Component: Monoclonal Antibodies Linker Cytotoxic Agent Others Breakup by Target: Antibody-Protein Toxin Conjugates Antibody-Chelated Radionuclide Conjugates Antibody-Small-Molecule Drug Conjugates Antibody-Enzyme Conjugates Breakup by Application: Lymphoma Ovarian Cancer Lung Cancer Breast Cancer Brain Tumor Others Breakup by End User: Hospitals Specialized Cancer Centers Academic Research Institutes Biotechnology Companies Others Breakup by Region: North America United States Canada Asia-Pacific China Japan India South Korea Australia Indonesia Others Europe Germany France United Kingdom Italy Spain Russia Others Latin America Brazil Mexico Others Middle East and Africa Competitive Landscape: The competitive landscape of the industry has also been examined along with the profiles of the key players being ADC Therapeutics SA, Astellas Pharma Inc., AstraZeneca plc, Celldex Therapeutics Inc., F. Hoffmann-La Roche AG, Gilead Sciences Inc., GlaxoSmithKline Plc, ImmunoGen Inc, Pfizer Inc., Sanofi S.A., Seagen Inc., Sorrento Therapeutics Inc. and Takeda Pharmaceutical Company Ltd. Key Questions Answered in This Report: How has the global antibody drug conjugates market performed so far and how will it perform in the coming years? What has been the impact of COVID-19 on the global antibody drug conjugates market? What are the key regional markets? What is the breakup of the market based on the component? What is the breakup of the market based on the target? What is the breakup of the market based on the application? What is the breakup of the market based on the end user? What are the various stages in the value chain of the industry? What are the key driving factors and challenges in the industry? What is the structure of the global antibody drug conjugates market and who are the key players? What is the degree of competition in the industry?

1 Preface 2 Scope and Methodology 2.1 Objectives of the Study 2.2 Stakeholders 2.3 Data Sources 2.3.1 Primary Sources 2.3.2 Secondary Sources 2.4 Market Estimation 2.4.1 Bottom-Up Approach 2.4.2 Top-Down Approach 2.5 Forecasting Methodology 3 Executive Summary 4 Introduction 4.1 Overview 4.2 Key Industry Trends 5 Global Antibody Drug Conjugates Market 5.1 Market Overview 5.2 Market Performance 5.3 Impact of COVID-19 5.4 Market Forecast 6 Market Breakup by Component 6.1 Monoclonal Antibodies 6.1.1 Market Trends 6.1.2 Market Forecast 6.2 Linker 6.2.1 Market Trends 6.2.2 Market Forecast 6.3 Cytotoxic Agent 6.3.1 Market Trends 6.3.2 Market Forecast 6.4 Others 6.4.1 Market Trends 6.4.2 Market Forecast 7 Market Breakup by Target 7.1 Antibody-Protein Toxin Conjugates 7.1.1 Market Trends 7.1.2 Market Forecast 7.2 Antibody-Chelated Radionuclide Conjugates 7.2.1 Market Trends 7.2.2 Market Forecast 7.3 Antibody-Small-Molecule Drug Conjugates 7.3.1 Market Trends 7.3.2 Market Forecast 7.4 Antibody-Enzyme Conjugates 7.4.1 Market Trends 7.4.2 Market Forecast 8 Market Breakup by Application 8.1 Lymphoma 8.1.1 Market Trends 8.1.2 Market Forecast 8.2 Ovarian Cancer 8.2.1 Market Trends 8.2.2 Market Forecast 8.3 Lung Cancer 8.3.1 Market Trends 8.3.2 Market Forecast 8.4 Breast Cancer 8.4.1 Market Trends 8.4.2 Market Forecast 8.5 Brain Tumor 8.5.1 Market Trends 8.5.2 Market Forecast 8.6 Others 8.6.1 Market Trends 8.6.2 Market Forecast 9 Market Breakup by End User 9.1 Hospitals 9.1.1 Market Trends 9.1.2 Market Forecast 9.2 Specialized Cancer Centers 9.2.1 Market Trends 9.2.2 Market Forecast 9.3 Academic Research Institutes 9.3.1 Market Trends 9.3.2 Market Forecast 9.4 Biotechnology Companies 9.4.1 Market Trends 9.4.2 Market Forecast 9.5 Others 9.5.1 Market Trends 9.5.2 Market Forecast 10 Market Breakup by Region 10.1 North America 10.1.1 United States 10.1.1.1 Market Trends 10.1.1.2 Market Forecast 10.1.2 Canada 10.1.2.1 Market Trends 10.1.2.2 Market Forecast 10.2 Asia-Pacific 10.2.1 China 10.2.1.1 Market Trends 10.2.1.2 Market Forecast 10.2.2 Japan 10.2.2.1 Market Trends 10.2.2.2 Market Forecast 10.2.3 India 10.2.3.1 Market Trends 10.2.3.2 Market Forecast 10.2.4 South Korea 10.2.4.1 Market Trends 10.2.4.2 Market Forecast 10.2.5 Australia 10.2.5.1 Market Trends 10.2.5.2 Market Forecast 10.2.6 Indonesia 10.2.6.1 Market Trends 10.2.6.2 Market Forecast 10.2.7 Others 10.2.7.1 Market Trends 10.2.7.2 Market Forecast 10.3 Europe 10.3.1 Germany 10.3.1.1 Market Trends 10.3.1.2 Market Forecast 10.3.2 France 10.3.2.1 Market Trends 10.3.2.2 Market Forecast 10.3.3 United Kingdom 10.3.3.1 Market Trends 10.3.3.2 Market Forecast 10.3.4 Italy 10.3.4.1 Market Trends 10.3.4.2 Market Forecast 10.3.5 Spain 10.3.5.1 Market Trends 10.3.5.2 Market Forecast 10.3.6 Russia 10.3.6.1 Market Trends 10.3.6.2 Market Forecast 10.3.7 Others 10.3.7.1 Market Trends 10.3.7.2 Market Forecast 10.4 Latin America 10.4.1 Brazil 10.4.1.1 Market Trends 10.4.1.2 Market Forecast 10.4.2 Mexico 10.4.2.1 Market Trends 10.4.2.2 Market Forecast 10.4.3 Others 10.4.3.1 Market Trends 10.4.3.2 Market Forecast 10.5 Middle East and Africa 10.5.1 Market Trends 10.5.2 Market Breakup by Country 10.5.3 Market Forecast 11 SWOT Analysis 11.1 Overview 11.2 Strengths 11.3 Weaknesses 11.4 Opportunities 11.5 Threats 12 Value Chain Analysis 13 Porters Five Forces Analysis 13.1 Overview 13.2 Bargaining Power of Buyers 13.3 Bargaining Power of Suppliers 13.4 Degree of Competition 13.5 Threat of New Entrants 13.6 Threat of Substitutes 14 Price Analysis 15 Competitive Landscape 15.1 Market Structure 15.2 Key Players 15.3 Profiles of Key Players 15.3.1 ADC Therapeutics SA 15.3.1.1 Company Overview 15.3.1.2 Product Portfolio 15.3.1.3 Financials 15.3.2 Astellas Pharma Inc 15.3.2.1 Company Overview 15.3.2.2 Product Portfolio 15.3.2.3 Financials 15.3.2.4 SWOT Analysis 15.3.3 AstraZeneca plc 15.3.3.1 Company Overview 15.3.3.2 Product Portfolio 15.3.3.3 Financials 15.3.3.4 SWOT Analysis 15.3.4 Celldex Therapeutics Inc 15.3.4.1 Company Overview 15.3.4.2 Product Portfolio 15.3.4.3 Financials 15.3.4.4 SWOT Analysis 15.3.5 F. Hoffmann-La Roche AG 15.3.5.1 Company Overview 15.3.5.2 Product Portfolio 15.3.5.3 Financials 15.3.6 Gilead Sciences Inc 15.3.6.1 Company Overview 15.3.6.2 Product Portfolio 15.3.6.3 Financials 15.3.6.4 SWOT Analysis 15.3.7 GlaxoSmithKline Plc 15.3.7.1 Company Overview 15.3.7.2 Product Portfolio 15.3.7.3 Financials 15.3.7.4 SWOT Analysis 15.3.8 ImmunoGen Inc 15.3.8.1 Company Overview 15.3.8.2 Product Portfolio 15.3.8.3 Financials 15.3.8.4 SWOT Analysis 15.3.9 Pfizer Inc 15.3.9.1 Company Overview 15.3.9.2 Product Portfolio 15.3.9.3 Financials 15.3.9.4 SWOT Analysis 15.3.10 Sanofi S.A 15.3.10.1 Company Overview 15.3.10.2 Product Portfolio 15.3.10.3 Financials 15.3.10.4 SWOT Analysis 15.3.11 Seagen Inc 15.3.11.1 Company Overview 15.3.11.2 Product Portfolio 15.3.11.3 Financials 15.3.11.4 SWOT Analysis 15.3.12 Sorrento Therapeutics Inc 15.3.12.1 Company Overview 15.3.12.2 Product Portfolio 15.3.12.3 Financials 15.3.13 Takeda Pharmaceutical Company Ltd 15.3.13.1 Company Overview 15.3.13.2 Product Portfolio 15.3.13.3 Financials 15.3.13.4 SWOT Analysis